Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Published:2013-03-26 Issue:9 Volume:19 Page:2541-2550
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Tabernero Josep,Garcia-Carbonero Rocio,Cassidy James,Sobrero Alberto,Van Cutsem Eric,Köhne Claus-Henning,Tejpar Sabine,Gladkov Oleg,Davidenko Irina,Salazar Ramon,Vladimirova Liubov,Cheporov Sergey,Burdaeva Olga,Rivera Fernando,Samuel Leslie,Bulavina Irina,Potter Vanessa,Chang Yu-Lin,Lokker Nathalie A.,O'Dwyer Peter J.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis;Heliyon;2024-08

2. Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors;Cancers;2024-03-20

3. Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects;Frontiers in Bioscience-Landmark;2024-02-04

4. VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis;Cancers;2023-10-16

5. Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001);Frontiers in Oncology;2023-09-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP